Nimenrix meningococcal group A, C, W-135 and Y conjugate vaccine
What is Nimenrix and what is it used for?
Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning).
The vaccine contains substances from the outer coat of the bacterium N. meningitidis.
How is Nimenrix used?
Nimenrix can only be obtained with a prescription and should be used according to available official recommendations. It is available as a powder and solvent that are mixed together to make a solution for injection. The powder is available in a vial, and the solvent is available in a pre-filled syringe or in an ampoule (a sealed container).
Nimenrix is given as an injection into the thigh or shoulder muscle. In children from 6 to 12 weeks of age, three doses of Nimenrix are recommended (the first dose is given from 6 weeks of age, the second dose 2 months afterwards, and the third booster dose at 1 year of age). In adults and children from 1 year of age, one injection is usually given. Nimenrix may also be used as a booster vaccine in people from 1 year of age who have already been vaccinated with Nimenrix or another meningococcal vaccine, to reinforce the level of protection.
For further information, see the package leaflet.
How does Nimenrix work?
Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. When a person is given the vaccine, the immune system recognises the parts of the bacterium contained in the vaccine as ‘foreign’ and makes antibodies against them. When the person is then exposed to the bacterium, these antibodies together with other components of the immune system will be ready to kill the bacteria and help protect against the disease.
Nimenrix contains small amounts of capsular polysaccharides (sugars from the outer coat) extracted from the four groups of the N. meningitidis bacterium: A, C, W135 and Y. These have been purified and then ‘conjugated’ (attached) to a protein carrier called tetanus toxoid (a weakened toxin of tetanus which does not cause disease, also used in tetanus vaccine), because this improves the immune response to the vaccine.
What benefits of Nimenrix have been shown in studies?
The ability of Nimenrix to trigger the production of antibodies (immunogenicity) was assessed in five main studies involving over 4,000 participants aged 1 year or more. Nimenrix was compared with several other similar vaccines against N. meningitidis. Results showed that a single injection of Nimenrix was as effective as the other vaccines in stimulating an immune response against all four types of N. meningitidis polysaccharides. The number of people who had an immune response against the polysaccharides with Nimenrix was similar to the other vaccines.
Studies also showed that, in people vaccinated with Nimenrix or another meningococcal vaccine when they were 1 year of age or older, Nimenrix given as a booster several years after they had been vaccinated increased the level of antibodies.
A sixth study in over 2,000 children first vaccinated between 6 and 12 weeks of age showed that Nimenrix (given as 2 doses 2 months apart) was as effective as two other vaccines against N. meningitides in stimulating an immune response.
What are the risks associated with Nimenrix?
The most common side effects from initial vaccination with Nimenrix (seen in more than 1 patient in 10) are loss of appetite, irritability, drowsiness, headache, fever, swelling, pain and redness at the site of injection, and tiredness. Side effects after booster vaccination with Nimenrix are generally similar to those after initial vaccination, but diarrhoea, vomiting and nausea are also very common. For the full list of all side effects and restrictions with Nimenrix, see the package leaflet.
Why is Nimenrix approved?
The CHMP considered that Nimenrix had been shown to be at least as effective as comparable vaccines at stimulating an immune response to the four groups of the N. meningitidis bacterium in people of different age groups. The Committee noted that Nimenrix offered the benefits of conjugated vaccines over conventional vaccines, including producing a strong immune response in young children. Nimenrix is well tolerated and the CHMP considered that it can be safely given together with other routinely used vaccines in the different age groups. Therefore, the CHMP decided that the benefits of Nimenrix are greater than its risks and recommended that it be granted marketing authorisation.
What measures are being taken to ensure the safe and effective use of Nimenrix?
The company that markets Nimenrix will carry out a study to assess how long the protective immune response provided by one or two doses of Nimenrix lasts in young children between 1 and 2 years old.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nimenrix have also been included in the summary of product characteristics and the package leaflet.
Other information about Nimenrix
The European Commission granted a marketing authorisation valid throughout the European Union for Nimenrix on 20 April 2012.
European Medicines Agency
This is a summary of the European public assessment report (EPAR) for Nimenrix. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Nimenrix.
The full EPAR for Nimenrix can be found in:
For more information about treatment with Nimenrix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This summary was last updated in 12-2016.